IP Library Granted Patent US 10,918,718
Granted Patent B2
US 10,918,718 · App. 15/031,199 · Granted Feb 16, 2021

Sonosensitive therapeutic or diagnostic agent

Inventors: Steven Mo (Oxford, GB); Robert Crispin Carlisle (Oxford, GB); Leonard W. Seymour (Oxford, GB); Constantin-Cassios Coussios (Oxford, GB)
Assignee: Oxsonics Limited
A61K41/0047A61K33/24A61K41/0028A61K47/60A61K47/6923A61K47/6929A61M37/0092A61M2037/0007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,918,718
App. No.
15/031,199
Granted
Feb 16, 2021
Kind
B2
Abstract

The invention disclosed herein relates to a method of cavitation-induced delivery of a therapeutic or diagnostic agent to a human or animal subject. In particular the invention provides an agent for use in a method of diagnosis or treatment of a human or animal subject, the method comprising exposing the subject to ultrasound, wherein the agent comprises a therapeutic or diagnostic component which is covalently bound to a dense component, the dense component having a density greater than that of the therapeutic or diagnostic component, and wherein either the dense component is a cavitation initiator or the method comprises administering to the subject a further agent which is a cavitation initiator. Binding of the dense component enhances cavitation-induced transport of the therapeutic or diagnostic component.

Claims (20)

1. A method of diagnosis or treatment of a human or animal subject, which method comprises administering to said subject an effective amount of an agent,

wherein the agent comprises a therapeutic or diagnostic component which is covalently bound to a dense component, the dense component having a density greater than that of the therapeutic or diagnostic component,

wherein the method comprises administering to the subject a further agent which is a cavitation initiator, said cavitation initiator being a substance comprising one or more gas or vapor filled cavities or bubbles, and

wherein the method further comprises exposing the subject to ultrasound, wherein the cavitation initiator undergoes inertial cavitation in the subject.

2. A method according to claim 1 , wherein the dense component has a density which is two times or more that of the therapeutic or diagnostic component.

3. A method according to claim 1 , wherein the agent has a density of 1.5 g/mL or more.

4. A method according to claim 1 , wherein the dense component is cleavably bound to the therapeutic or diagnostic component.

5. A method according to claim 4 , wherein the dense component is bound to the therapeutic or diagnostic component with a polymer chain comprising a cleavable moiety.

6. A method according to claim 1 , wherein the dense component comprises a nanoparticle from 1 to 1000 nm in size.

7. A method according to claim 6 , wherein the dense component comprises a nanoparticle of a metal.

8. A method according to claim 7 , wherein the metal is gold.

9. A method according to claim 6 , wherein the nanoparticle has a plurality of polymer chains attached thereto.

10. A method according to claim 8 , wherein the nanoparticle has a plurality of polymer chains attached thereto.

11. A method according to claim 1 , wherein said cavitation initiator comprises an agglomerate of carbon nanoparticles.

12. A method according to claim 1 , wherein the subject is exposed to ultrasound at an ultrasound pressure amplitude of less than 5 MPa.

13. A method according to claim 12 , wherein the subject is exposed to ultrasound at an ultrasound pressure amplitude of 3 MPa or less.

14. A method according to claim 1 , which is a method of treating a tumor in a patient in need thereof.

15. A method according to claim 1 , wherein the agent has a size of from 100 to 500 nm.

16. A method according to claim 14 , wherein the agent has a size of from 100 to 500 nm.

17. A method according to claim 1 , wherein the subject is exposed to ultrasound at an ultrasound pressure of at least 0.5 MPa.

Assignments (3)
CHANGE OF NAME Recorded Jul 17, 2017
From: OXFORD UNIVERSITY INNOVATION LIMITED
To: OXSONICS LIMITED
Reel/Frame 043025/0980 →
CHANGE OF NAME Recorded Aug 2, 2016
From: ISIS INNOVATION LIMITED
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 039550/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: MO, STEVEN; CARLISLE, ROBERT CRISPIN; SEYMOUR, LEONARD W.; COUSSIOS, CONSTANTIN-CASSIOS
To: ISIS INNOVATION LIMITED
Reel/Frame 039229/0951 →